result weak even tougher model y/i guidanc
buyback suspend action improv near term ep outlook
expect long-term growth profit remain larg unchang
maintain market perform rate price target dcf price-to-earnings
revenu declin y/i cc result revenu
forecast though miss consensu remind made
signific cut expect account late march link china
y/i cc primari driver downsid repres overal headwind
growth outsid china manag note growth last week
quarter govern action drove materi weak us eu
product categori weak primarili driven instrument declin
y/i cc recur revenu y/i cc end market pharma
y/i cc industrial/appli y/i cc acc/gov y/i cc declin
quarter page detail
gross margin y/i forecast oper margin
y/i came expect ep declin y/i
better expect tax rate non-oper item ad ep
manag withdrew guidanc announc suspens plan
buyback previou guidanc purchas manag also
announc cost action reduc annual expens opex
cog rais ep forecast accordingli partial due higher
revenu estim though mostli due cost action
offici guidanc provid manag indic expect
challeng y/i declin consist expect
seemingli assum y/i growth china improv vs though remain
significantli increas revenu forecast modestli though continu
model revenu y/i
result tough even wors howev larg
expect increment cost action improv near-term ep outlook importantli
believ today result chang long- term growth profit trajectori
busi maintain price target base dcf analysi
repres ep forecast
pleas see page report import disclosur
past year organ revenu growth deceler peer
group averag manag execut also disappoint particularli rel
peer result past sever quarter suggest return least
sustain peer group level revenu growth immin price target
base dcf analysi repres ep forecast think
adequ justifi reflect aforement factor
revenu growth improv
favor comparison
long-term ep growth msd-hsd
revenu growth acceler hsd/ldd
driven easi comparison
solid cash flow return profil
buyback return forc late
transact well receiv
macroeconom competit
current expect
limit room margin improv
caus investor revisit inher
growth rate compani appropri
corpor analyt instrument manufactur
divis design manufactur sell servic high-perform liquid
chromatographi hplc ultra perform liquid chromatographi uplc togeth
hplc refer lc mass spectrometri ms instrument system support
product includ chromatographi column consum product post-
warranti servic plan ta divis ta compani primarili design
manufactur sell servic thermal analysi rheometri calorimetri instrument
compani also develop supplier software-bas product interfac
compani instrument well manufactur instrument
compani report thomson eikon cowen compani
cowen vs consensu mm except cc fx y/i headwind cc growthgross revenu metric mm except statement mm except currenc per count ep beat forecast though miss consensu lower expect tax rate non-oper item ad divis revenu y/i cc came forecast instrument declin y/i manag blame nearli weak china though also note weaken trend late quarter us/europe/india recur revenu declin y/i everi end market declin y/i includ y/i declin pharma manag note overal compani growth ex-china last week quarter ta sale y/i cc came forecast instrument declin y/i cc servic modestli y/i industri end market revenu declin y/i manag sound optimist demand polym custom return new product aid revenu y/i beat forecast though miss consensu rel expect everi product area weak particular weak instrument y/i china revenu y/i equat total compani headwind pharma y/i industri y/i acc/gov y/i declin quarter gross margin came forecast consensu despit lower expect instrument mix forecast sale sg forecast sale oper profit forecast oper margin forecast lower expect lower expect cowen
compani report thomson eikon cowen compani
mm except cagrcommentsnet guidanc suspend cc challeng one less day y/yorgan two extra day y/yconst currenc guidanc suspend cost action vs prior plan within oper cost action vs prior plan within opex littl remaind guidanc suspend oper margin cost action vs prior plan within littl remaind non-oper interest guidanc suspend earn per guidanc suspend guidanc suspend cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk upsid includ limit recoveri macroeconom condit
increas client budget demand lc/m instrument consum better-than-
expect product innov associ revenu contribut share gain risk
downsid includ limit macroeconom deterior current
level inabl execut integr eros market share price due
competit inabl deliv incremental/decrement margin target value-
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank
servic past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc april et dissemin april et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
